Literature DB >> 25458227

Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.

R J Schipper1, M Moossdorff2, R G H Beets-Tan3, M L Smidt2, M B I Lobbes4.   

Abstract

OBJECTIVE: To provide a systematic review of studies comparing the diagnostic performance of noninvasive techniques and axillary lymph node dissection in the identification of initially node positive patients with pathological complete response of axillary lymph nodes to neoadjuvant systemic therapy.
METHODS: PubMed and Embase databases were searched until May 21st, 2014. First, duplicate studies were eliminated. Next, study abstracts were read by two readers to assess eligibility. Studies were selected based on predefined inclusion criteria. Of these, data extraction was performed by two readers independently.
RESULTS: Of the 987 abstracts that were considered for inclusion, four were eligible for final analysis, which included a total of 572 patients. The diagnostic performance of clinical examination, axillary ultrasound, breast MRI, whole body (18)F-FDG PET-CT, and a prediction model to identify patients with pathological complete response were investigated. Studies were often limited by small sample size. Furthermore, systemic therapy regimens and definitions of clinical and pathological complete response were variable, refraining further pooling of data. The reported positive predictive value of different techniques to identify patients with axillary pathological complete response after neoadjuvant systemic therapy varied between 40% and 100%.
CONCLUSION: At present, there is no accurate noninvasive restaging technique able to identify patients with complete axillary response after neoadjuvant systemic therapy.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Avoiding morbidity; Breast cancer; Nodal re staging; Noninvasive; Personalized medicine

Mesh:

Substances:

Year:  2014        PMID: 25458227     DOI: 10.1016/j.ejrad.2014.09.020

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  11 in total

1.  Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).

Authors:  David W Ollila; Constance T Cirrincione; Donald A Berry; Lisa A Carey; William M Sikov; Clifford A Hudis; Eric P Winer; Mehra Golshan
Journal:  J Am Coll Surg       Date:  2017-01-13       Impact factor: 6.113

2.  Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.

Authors:  Rosalind P Candelaria; Roland L Bassett; William Fraser Symmans; Maheshwari Ramineni; Stacy L Moulder; Henry M Kuerer; Alastair M Thompson; Wei Tse Yang
Journal:  Oncologist       Date:  2017-03-17

3.  MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Joseph J Weber; Maxine S Jochelson; Anne Eaton; Emily C Zabor; Andrea V Barrio; Mary L Gemignani; Melissa Pilewskie; Kimberly J Van Zee; Monica Morrow; Mahmoud El-Tamer
Journal:  J Am Coll Surg       Date:  2017-09-15       Impact factor: 6.113

4.  Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.

Authors:  Na Lae Eun; Eun Ju Son; Hye Mi Gweon; Jeong-Ah Kim; Ji Hyun Youk
Journal:  Eur Radiol       Date:  2019-12-04       Impact factor: 5.315

5.  Predicting axillary response to neoadjuvant chemotherapy: the role of diffusion weighted imaging.

Authors:  Lucia Graña-López; Tania Pérez-Ramos; Fiz Andrés Maciñeira; Ángeles Villares; Manuel Vázquez-Caruncho
Journal:  Br J Radiol       Date:  2021-11-10       Impact factor: 3.039

6.  Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.

Authors:  S You; D K Kang; Y S Jung; Y-S An; G S Jeon; T H Kim
Journal:  Br J Radiol       Date:  2015-08       Impact factor: 3.039

7.  Accuracy of axillary ultrasound after different neoadjuvant chemotherapy cycles in breast cancer patients.

Authors:  Bei-Bei Ye; Hong-Meng Zhao; Yue Yu; Jie Ge; Xin Wang; Xu-Chen Cao
Journal:  Oncotarget       Date:  2017-05-30

8.  Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

Authors:  Liyan Du; Xiaomei Li; Linhong Zhen; Weiling Chen; Lingguang Mu; Yang Zhang; Ailin Song
Journal:  Mol Med Rep       Date:  2018-03-16       Impact factor: 2.952

9.  Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.

Authors:  Samia Al-Hattali; Sarah J Vinnicombe; Nazleen Muhammad Gowdh; Andrew Evans; Sharon Armstrong; Douglas Adamson; Colin A Purdie; E Jane Macaskill
Journal:  Cancer Imaging       Date:  2019-12-26       Impact factor: 3.909

10.  Histologic Grade and Decrease in Tumor Dimensions Affect Axillary Lymph Node Status after Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Tae Hee Kim; Doo Kyoung Kang; Ji Young Kim; Sehwan Han; Yongsik Jung
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.